Summary
Abatacept has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Psoriatic Arthritis would be drug repurposing rather than first-in-human development. This does not mean it is approved for Psoriatic Arthritis. ClinicalTrials.gov lists 8 registered trials linking Abatacept to Psoriatic Arthritis: 1 is currently recruiting; 1 is active or not yet recruiting; 5 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT05080218). The largest enrolment is 38396 participants (NCT05421442). Registration activity spans 2006 to 2025. The literature layer holds 12 publications for this pair: 5 Cochrane reviews, 1 systematic review, 1 randomised controlled trial publication and 5 clinical trial publications. Publication years run from 2015 to 2023. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Psoriatic Arthritis ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous remission uncommon (<5%); progressive joint damage in 40-60% without adequate treatment; enthesitis, dactylitis, axial involvement accumulate over time.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 75.5 (trials 25.5, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 1 recruiting, 1 active / not yet recruiting, 5 completed, 1 other |
| Linked publications | 12 (5 Cochrane reviews, 5 clinical trial publications, 1 systematic review, 1 randomised controlled trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | CD80 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05080218 | COVID-19 VaccinE Response in Rheumatology Patients 2021 | completed | Phase 4 | 841 |
| NCT04106804 | Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker 2018 | status unknown | Phase 4 | 20 |
| NCT01860976 | Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis 2013 | completed | Phase 3 | 489 |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty 2025 | not yet recruiting | Phase 2 | 80 |
| NCT03496831 | Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs 2006 | completed | Not applicable | 7,500 |
| NCT05421442 | A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database 2019 | completed | Not applicable | 38,396 |
| NCT03419143 | Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants 2018 | completed | Not applicable | 190 |
| NCT01965132 | Korean College of Rheumatology Biologics and Targeted Therapy Registry 2012 | recruiting | Not applicable | 10,000 |
Published literature
- Cochrane review Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic reviewGialouri CG, Pappa M, Evangelatos G et al. · Autoimmunity reviews · 2023 · PMID 37150489
- Clinical trial publication Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritisØstergaard M, Bird P, Pachai C et al. · Rheumatology (Oxford, England) · 2022 · PMID 35137002
- Cochrane review Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-AnalysisWang SH, Yu CL, Wang TY et al. · Pharmaceutics · 2022 · PMID 36297574
- Systematic review Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature ReviewChessa E, Piga M, Floris A et al. · BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021 · PMID 33595833
- Clinical trial publication Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritisMease PJ, McInnes IB, Strand V et al. · Rheumatology international · 2020 · PMID 32356115
- Cochrane review Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritisKerschbaumer A, Smolen JS, Dougados M et al. · Annals of the rheumatic diseases · 2020 · PMID 32381564
- Cochrane review Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative reviewMekhail C, Chouk M, Prati C et al. · Expert review of clinical pharmacology · 2020 · PMID 32306777
- Cochrane review Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomesSimons N, Degboé Y, Barnetche T et al. · Clinical and experimental rheumatology · 2020 · PMID 31969228
- Clinical trial publication Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trialStrand V, Alemao E, Lehman T et al. · Arthritis research & therapy · 2018 · PMID 30522501
- Clinical trial publication Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritisSzentpetery A, Heffernan E, Gogarty M et al. · Arthritis research & therapy · 2017 · PMID 28679449
- Clinical trial publication Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritisMease PJ, Gottlieb AB, van der Heijde D et al. · Annals of the rheumatic diseases · 2017 · PMID 28473423
- Randomized controlled trial Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled TrialGlinatsi D, Bird P, Gandjbakhch F et al. · The Journal of rheumatology · 2015 · PMID 26523032
Mechanism and notes
Recorded mechanism or class: inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CD80. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Abatacept approved for Psoriatic Arthritis?
Abatacept has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Psoriatic Arthritis would be drug repurposing rather than first-in-human development. This does not mean it is approved for Psoriatic Arthritis. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Abatacept in clinical trials for Psoriatic Arthritis?
ClinicalTrials.gov lists 8 registered trials linking Abatacept to Psoriatic Arthritis: 1 is currently recruiting; 1 is active or not yet recruiting; 5 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT05080218). The largest enrolment is 38396 participants (NCT05421442). Registration activity spans 2006 to 2025.
What does the evidence show for Abatacept in Psoriatic Arthritis?
Abatacept has both completed registered trials and synthesis-level publications linked to Psoriatic Arthritis. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CD80. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.